Additional information: Cyxone to explore options for faster market approval

Due to the interview conducted with Cyxone's CEO by BioStock/Monocl on Thursday, September 28, the company wishes to clarify references made about the extent to which two Phase 2 trials may be equated with a Phase 3 trial.

The regulatory framework relating to drug trials exists to ensure that development companies present significant and reproducable results involving candidate substances so that effectiveness and safety are established using the best scientifc methods prior to a company being able to market a product.

In certain cases it is possible that if two or more Phase 2 trials are conducted in the same way, the results from two trials may be considered as a single trial in statistical terms. It is the responsibiltiy of drug agencies to evaluate whether this can be permitted.

If drug agencies deem the combined analysis of several trials to be the equivalent of a larger follow-up trial, (so called Phase 3), and that the results are sufficiently strong to justify this, this may constitute sufficient grounds to submit an application to authorities responsible for marketing rights.

In the interview with BioStock/Monocl, Cyxone's CEO said that it was possible that Rabeximod may fall into this category, and that Cyxone intends to establish a dialogue with drug agencies at a later date. Prior to that, the company needs to conduct a six-month toxicity study followed by a new Phase 2 trial.

October 5, 2017

Contact
Cyxone AB (publ)
Kjell G. Stenberg, CEO
Tel: +46 (0)723 816168
Email: kjell.g.stenberg@cyxone.com
Adelgatan 21
211 22 Malmö
www.cyxone.com

This is information that Cyxone AB is required to publish under the EU Market Abuse Directive. The information was provided under the auspices of the above contact person for publication on October 3, 2017 at 11:55 CET. Press release Cyxone AB (publ) 559020-5471 October 5, 2017

About Cyxone 
Cyxone AB (publ.) is a biopharmaceutical company that develops drugs based on cyclotides, a class of natural plant protein. Cyclotide technology has the potential to provide new drugs with beneficial pharmacological effects on diseases that currently lack safe and effective treatments. The company is focusing on the development of substances that inhibit key processes in cells that are typically associated with various immune disorders, such as multiple sclerosis and rheumatoid arthritis. Cyxone's Certified Adviser on the Nasdaq First North is Erik Penser Bank, which can be reached on +46 (0) 8 46 38 000. www.cyxone.com

About Us

Cyxone AB is a clinical stage biotech company with a portfolio of immunomodulating drugs for the treatment of autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis (RA). The company’s drug portfolio is based on two technological pillars in the form of oral molecules and cyclotide-based drugs that inhibit key processes in the body’s cells that are typically associated with various immune-related disorders. Cyxone’s technologies have the potential to address an unmet need and provide new effective and safe medicines that can improve the quality of life for patients affected by autoimmune diseases. The company has two drug candidates, T20K for MS in a preclinical program and Rabeximod for RA in clinical phase II-program. Cyxone’s Certified Adviser on the Nasdaq First North is Erik Penser Bank, +46 (0)8 4638000.www.cyxone.com

Subscribe

Documents & Links